Tandem Diabetes (TNDM) Misses Q1 EPS by 23c, Beats on Revenues; Offers FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tandem Diabetes Care (TNDM) PT Raised to $7.50 at Stifel
April 27, 2018 10:32 AM EDTStifel raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $7.50 while maintaining a Hold rating.
... MoreTandem Diabetes Care (TNDM) PT Raised to $9 at Cowen; More Upside
April 27, 2018 7:48 AM EDTCowen raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $9.00 (from $7.00) while maintaining a Outperform rating.
Analyst Doug Schenkel commented, "TNDM posted a solid Q1 beat. We expect numerous revenue growth catalysts (new products, renewals, Animas, international, infusion sets) to drive upside to... More
